HU9203371D0 - Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5 - Google Patents

Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5

Info

Publication number
HU9203371D0
HU9203371D0 HU9203371A HU9203371A HU9203371D0 HU 9203371 D0 HU9203371 D0 HU 9203371D0 HU 9203371 A HU9203371 A HU 9203371A HU 9203371 A HU9203371 A HU 9203371A HU 9203371 D0 HU9203371 D0 HU 9203371D0
Authority
HU
Hungary
Prior art keywords
them5
icam
antibodies
producing
grafted anti
Prior art date
Application number
HU9203371A
Other languages
English (en)
Inventor
John Robert Adair
Diljeet Singh Athwal
Robert Rothlein
Original Assignee
Celltech Ltd
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd, Boehringer Ingelheim Pharma filed Critical Celltech Ltd
Publication of HU9203371D0 publication Critical patent/HU9203371D0/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HU9203371A 1990-04-27 1992-10-27 Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5 HU9203371D0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009549A GB9009549D0 (en) 1990-04-27 1990-04-27 Recombinant antibody and method

Publications (1)

Publication Number Publication Date
HU9203371D0 true HU9203371D0 (en) 1993-01-28

Family

ID=10675134

Family Applications (2)

Application Number Title Priority Date Filing Date
HU923371A HUT62652A (en) 1990-04-27 1991-04-29 Process for producing humqnized cdr-inoculated anti-icam-1 antibodies
HU9203371A HU9203371D0 (en) 1990-04-27 1992-10-27 Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU923371A HUT62652A (en) 1990-04-27 1991-04-29 Process for producing humqnized cdr-inoculated anti-icam-1 antibodies

Country Status (8)

Country Link
EP (1) EP0528951A4 (hu)
JP (1) JPH06500229A (hu)
AU (1) AU7900191A (hu)
BR (1) BR9106392A (hu)
CA (1) CA2081478A1 (hu)
GB (1) GB9009549D0 (hu)
HU (2) HUT62652A (hu)
WO (1) WO1991016927A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
WO1994007921A1 (en) * 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
EP1163003B1 (en) 1999-03-19 2009-08-12 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
AU777241B2 (en) * 1999-06-24 2004-10-07 Johns Hopkins University, The Compositions and methods for preventing transepithelial transmission of HIV
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
CA2478833C (en) * 2002-03-13 2015-11-10 Biogen, Inc. Anti-.alpha.v.beta.6 antibodies
CA2568570A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP5890017B2 (ja) * 2011-07-05 2016-03-22 ダイノナ インコーポレーテッド 抗原特異的ｔ細胞寛容を誘導する抗体およびその使用
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation

Also Published As

Publication number Publication date
GB9009549D0 (en) 1990-06-20
EP0528951A4 (en) 1993-05-26
EP0528951A1 (en) 1993-03-03
BR9106392A (pt) 1993-04-27
HUT62652A (en) 1993-05-28
AU7900191A (en) 1991-11-27
JPH06500229A (ja) 1994-01-13
CA2081478A1 (en) 1991-10-28
WO1991016927A1 (en) 1991-11-14

Similar Documents

Publication Publication Date Title
HU9203371D0 (en) Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
EP0539970A3 (en) Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
HU896763D0 (en) Process for the preparation of bispecific monoclonal antibody
IL97128A (en) Method for production of human monoclonal antibodies in non-human chimeric mammals
HU912820D0 (en) Method for producing 1-triptophane
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
AU1241795A (en) Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0361902A3 (en) Method for the reduction of heterogeneity of monoclonal antibodies
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
HUT63205A (en) Process for producing monoclonal antibodies and their fragments
GB2158094B (en) Anti-human igg monoclonal antibody and process for preparing the same
EP0506523A3 (en) Monoclonal antibodies
HU9301807D0 (en) Method for producing dinitro-toluols
EP0519728A3 (en) Anti-tcf-ii monoclonal antibodies and method for the measurement of tcf-ii by applying the antibodies
IL97827A0 (en) Monoclonal anti-igm antibodies,their production and use,and hybridomas for producing them
DE3379055D1 (en) Method for producing human antibody
EP0582450A3 (en) Antibodies against oxytocin receptor and their production.
AU9143991A (en) Monoclonal antibody op-g2 and method of use
EP0446763A3 (en) Antigen for producing anti-idiotype antibody, anti-idiotype antibody and method for producing the anti-idiotype antibody
IL71877A0 (en) Process for obtaining monoclonal antibodies
EP0533841A4 (en) Novel methods for producing antigen-specific, high-affinity human monoclonal antibodies
AU5083193A (en) Method for making humanized antibodies
HU913943D0 (en) Substituted dibenz-oxa-thiocinones and method for producing said compounds